Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-385-8 | CAS number: 120-32-1
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
The toxicokinetic behaviour of the test substance was assessed in male rats after oral, dermal and intravenous administration of radioactively labelled test substance (Kao and Birnbaum, 1986). The test substance was not completely absorbed from the gastrointestinal tract and skin and was shown to be distributed to organs, metabolized and excreted via urine and faeces.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 70
- Absorption rate - dermal (%):
- 62
Additional information
Groups of male Fischer 344 rats received 14C-labelled test substance by the oral, dermal, and intravenous route.
Oral doses were 10, 100, and 1000 mg/kg bw. Intravenous and dermal applications administered 10 mg/kg bw. An additional experiment was conducted to monitor the excretion of radioactivity into bile.
Excreta were collected over a period of 3 days after which the animals were sacrificed and tissues were collected. Expired air was sampled to monitor volatile metabolites.
The samples were analysed by thin layer chromatography (TLC), high performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS).
Three days after oral administration of [14C]-test substance at 10, 100, or 1000 mg/kg bw, more than 90% of each dose was excreted in urine and faeces. Comparison of disposition after intravenous, dermal, or oral administration indicated that the test substance was not completely absorbed from the gastrointestinal tract or skin. An oral absorption of 70 % was concluded. Dermal absorption was found to be approximately 62 %.
Most of the administered test substance was excreted and the tissue levels were generally low within 3 days post administration (except for the dermal study where 32 % of the total dose was found at the skin site). However, the highest concentration of test substance-derived radioactivity was found in the kidney during the whole measuring period. In addition, the studies also indicated that enterohepatic circulation was involved in disposition. Biliary excretion of the test substance was dose-dependent, with proportionally less test substance-derived radioactivity being excreted in the bile as the dose was raised. The major in vivo metabolites were glucuronyl conjugates of the test substance and hydroxylated test substance. Glutathione conjugates were also present in urine.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
